UroGen Pharma
UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. The last earnings update was 11 days ago. More info.
Add to Portfolio Compare Print
URGN Share Price and Events
7 Day Returns
1 Year Returns
URGN Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| UroGen Pharma (URGN) | 2% | 4.7% | -5.2% | -39.1% | - | - |
| US Biotechs | -1.6% | -5.5% | -6.5% | -5.5% | 9.7% | 12% |
| US Market | -0.7% | -2% | 2.4% | 3% | 39.2% | 42% |
1 Year Return vs Industry and Market
- URGN underperformed the Biotechs industry which returned -5.5% over the past year.
- URGN underperformed the Market in United States of America which returned 3% over the past year.
Value
Is UroGen Pharma undervalued based on future cash flows and its price relative to the stock market?
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current
share
price of
UroGen Pharma
to its discounted cash flow analysis.value.The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Below are the data sources, inputs and calculation used to determine the intrinsic value for UroGen Pharma.
| Data Point | Source | Value |
|---|---|---|
| Valuation Model | 2 Stage Free Cash Flow to Equity | |
| Levered Free Cash Flow | Average of 7 Analyst Estimates (S&P Global) | See below |
| Discount Rate (Cost of Equity) | See below | 10.2% |
| Perpetual Growth Rate | 10-Year US Government Bond Rate | 2.7% |
An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.
| Data Point | Calculation/ Source | Result |
|---|---|---|
| Risk-Free Rate | 10-Year US Govt Bond Rate | 2.7% |
| Equity Risk Premium | S&P Global | 6% |
| Biotechs Unlevered Beta | Simply Wall St/ S&P Global | 1.38 |
| Re-levered Beta | = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.379 (1 + (1- 21%) (0.4%)) |
1.257 |
| Levered Beta | Levered Beta limited to 0.8 to 2.0 (practical range for a stable firm) |
1.26 |
| Discount Rate/ Cost of Equity |
= Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (1.257 * 5.96%) |
10.22% |
Discounted Cash Flow Calculation for NasdaqGM:URGN using 2 Stage Free Cash Flow to Equity Model
The calculations below outline how an intrinsic value for UroGen Pharma is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.
| Levered FCF (USD, Millions) | Source |
Present Value Discounted (@ 10.22%) |
|
|---|---|---|---|
| 2019 | -105.00 | Analyst x1 | -95.26 |
| 2020 | -74.00 | Analyst x2 | -60.91 |
| 2021 | 11.00 | Analyst x2 | 8.21 |
| 2022 | -41.00 | Analyst x1 | -27.78 |
| 2023 | 133.50 | Analyst x2 | 82.07 |
| 2024 | 216.83 | Est @ 62.42% | 120.93 |
| 2025 | 313.34 | Est @ 44.51% | 158.55 |
| 2026 | 413.53 | Est @ 31.98% | 189.84 |
| 2027 | 509.48 | Est @ 23.2% | 212.20 |
| 2028 | 596.40 | Est @ 17.06% | 225.37 |
| Present value of next 10 years cash flows | $813.22 | ||
| Calculation | Result | |
|---|---|---|
| Terminal Value |
= FCF2028
× (1 + g) ÷ (Discount Rate – g)
= $596.40 × (1 + 2.73%) ÷ (10.22% – 2.73%) |
$8,178.98 |
| Present Value of Terminal Value |
= Terminal Value ÷ (1 + r)10
= $8,178.98 ÷ (1 + 10.22%)10 |
$3,090.70 |
| Calculation | Result | |
|---|---|---|
| Total Equity Value |
= Present value of next 10 years cash flows +
Terminal Value
= $813.22 + $3,090.70 |
$3,903.92 |
| Equity Value per Share (USD) |
= Total value / Shares Outstanding
= $3,903.92 / 20.79 |
$187.77 |
| Calculation | Result | |
|---|---|---|
| Value per share (USD) | From above. | $187.77 |
| Current discount | Discount to share price of
$38.28
= -1 x ($38.28 - $187.77) / $187.77 |
79.6% |
Learn more about our DCF calculations in Simply Wall St’s analysis model .
Current Discount
Current Discount Checks
- UroGen Pharma's share price is below the future cash flow value, and at a moderate discount (> 20%).
- UroGen Pharma's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for UroGen Pharma's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
UroGen Pharma's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2019-03-31) in USD | $-4.99 |
| NasdaqGM:URGN Share Price ** | NasdaqGM (2019-05-17) in USD | $38.28 |
| United States of America Biotechs Industry PE Ratio | Median Figure of 34 Publicly-Listed Biotechs Companies | 19.48x |
| United States of America Market PE Ratio | Median Figure of 3,088 Publicly-Listed Companies | 17.89x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of UroGen Pharma.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = NasdaqGM:URGN Share Price ÷ EPS (both in USD) = 38.28 ÷ -4.99 |
-7.67x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- UroGen Pharma is loss making, we can't compare its value to the US Biotechs industry average.
- UroGen Pharma is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does
UroGen Pharma's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | -7.67x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts |
45.4%per year |
| United States of America Biotechs Industry PEG Ratio | Median Figure of 27 Publicly-Listed Biotechs Companies | 1.32x |
| United States of America Market PEG Ratio | Median Figure of 2,117 Publicly-Listed Companies | 1.56x |
*Line of best fit is calculated by linear regression .
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to calculate PEG ratio for UroGen Pharma, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on
UroGen Pharma's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2019-03-31) in USD | $11.54 |
| NasdaqGM:URGN Share Price * | NasdaqGM (2019-05-17) in USD | $38.28 |
| United States of America Biotechs Industry PB Ratio | Median Figure of 416 Publicly-Listed Biotechs Companies | 3.21x |
| United States of America Market PB Ratio | Median Figure of 5,195 Publicly-Listed Companies | 1.83x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = NasdaqGM:URGN Share Price ÷ Book Value per Share (both in USD) = 38.28 ÷ 11.54 |
3.32x |
* Primary Listing of UroGen Pharma.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- UroGen Pharma is overvalued based on assets compared to the US Biotechs industry average.
Value checks
We assess UroGen Pharma's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check) UroGen Pharma has a total score of 2/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
Future Performance
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- UroGen Pharma's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
- UroGen Pharma's earnings growth is expected to exceed the United States of America market average.
- UroGen Pharma's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| NasdaqGM:URGN Future Earnings Growth Rate | Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts | 45.4% |
| NasdaqGM:URGN Future Revenue Growth Rate | Line of Best Fit* through Consensus Estimate Revenue of 7 Analysts | 63.6% |
| United States of America Biotechs Industry Earnings Growth Rate | Market Cap Weighted Average | 22.6% |
| United States of America Biotechs Industry Revenue Growth Rate | Market Cap Weighted Average | 17.5% |
| United States of America Market Earnings Growth Rate | Market Cap Weighted Average | 13.9% |
| United States of America Market Revenue Growth Rate | Market Cap Weighted Average | 7.3% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (1 month ago) | See Below |
| Future Estimates | Average of up to 7 Analyst Estimates (S&P Global) | See Below |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-12-31 | 292 | 257 | -14 | 5 |
| 2022-12-31 | 224 | 138 | 9 | 6 |
| 2021-12-31 | 120 | 31 | -66 | 6 |
| 2020-12-31 | 51 | -44 | -87 | 7 |
| 2019-12-31 | 0 | -82 | -106 | 6 |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2019-03-31 | 1 | -46 | -84 |
| 2018-12-31 | 1 | -37 | -76 |
| 2018-09-30 | 1 | -33 | -62 |
| 2018-06-30 | 9 | -21 | -42 |
| 2018-03-31 | 9 | -16 | -30 |
| 2017-12-31 | 8 | -10 | -21 |
| 2017-09-30 | 25 | 10 | 2 |
| 2017-06-30 | 18 | 4 | -7 |
| 2017-03-31 | 18 | 4 | -4 |
| 2016-12-31 | 18 | 4 | -4 |
| 2016-09-30 | -11 | -24 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (1 month ago) | See Below |
| Future Estimates | Average of up to 7 Analyst Estimates (S&P Global) | See Below |
All data from UroGen Pharma Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-12-31 | 1.68 | 8.37 | -2.13 | 4.00 |
| 2022-12-31 | 0.57 | 7.74 | -4.77 | 5.00 |
| 2021-12-31 | -2.90 | -0.25 | -4.62 | 4.00 |
| 2020-12-31 | -4.48 | -3.26 | -6.27 | 6.00 |
| 2019-12-31 | -5.47 | -5.15 | -5.83 | 5.00 |
| Date (Data in USD Millions) | EPS * |
|---|---|
| 2019-03-31 | -4.99 |
| 2018-12-31 | -4.80 |
| 2018-09-30 | -4.04 |
| 2018-06-30 | -2.86 |
| 2018-03-31 | -2.33 |
| 2017-12-31 | -2.14 |
| 2017-09-30 | 0.23 |
| 2017-06-30 | -1.67 |
| 2017-03-31 | -1.85 |
| 2016-12-31 | -1.91 |
| 2016-09-30 | -10.48 |
*GAAP earnings excluding extraordinary items.
Performance in 3 years
In the same way as past performance we look at the future estimated return
(profit) compared to the available
funds. We do this looking forward 3 years.
- Unable to establish if UroGen Pharma will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
Future performance checks
We assess UroGen Pharma's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
UroGen Pharma has a total score of 5/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
Past Performance
How has UroGen Pharma performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- UroGen Pharma does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
- Unable to compare UroGen Pharma's 1-year earnings growth to the 5-year average as it is not currently profitable.
- Unable to compare UroGen Pharma's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
All data from UroGen Pharma Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2019-03-31 | 0.65 | -83.72 | 38.71 | 36.64 |
| 2018-12-31 | 1.13 | -75.66 | 32.07 | 34.53 |
| 2018-09-30 | 1.46 | -62.03 | 25.06 | 30.57 |
| 2018-06-30 | 8.98 | -41.79 | 21.91 | 28.28 |
| 2018-03-31 | 8.62 | -30.19 | 14.01 | 23.66 |
| 2017-12-31 | 8.16 | -20.83 | 8.81 | 18.70 |
| 2017-09-30 | 25.36 | 1.56 | 6.60 | 14.31 |
| 2017-06-30 | 17.55 | -6.75 | 7.64 | 11.56 |
| 2017-03-31 | 17.55 | -4.27 | 6.39 | 10.26 |
| 2016-12-31 | 17.53 | -4.41 | 6.42 | 10.29 |
| 2016-09-30 | -24.14 | 6.07 | 13.99 | |
| 2016-03-31 | -15.56 | 2.61 | 11.37 | |
| 2015-12-31 | -13.54 | 1.90 | 10.52 | |
| 2015-09-30 | -7.39 | 1.29 | 5.35 | |
| 2014-12-31 | -4.56 | 0.89 | 3.48 | |
| 2013-12-31 | -3.31 | 1.06 | 2.33 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- It is difficult to establish if UroGen Pharma has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
- It is difficult to establish if UroGen Pharma has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
- It is difficult to establish if UroGen Pharma improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Past performance checks
We assess UroGen Pharma's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
UroGen Pharma has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
Health
How is UroGen Pharma's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up UroGen Pharma's finances.
The net worth of a company is the difference between its assets and liabilities.
- UroGen Pharma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- UroGen Pharma's cash and other short term assets cover its long term commitments.
Balance sheet
Assets
Liabilities and shares
- Low level of unsold assets.
- Debt is covered by short term assets, assets are 78x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from UroGen Pharma Company Filings, last reported 1 month ago.
| Date (Data in USD Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2019-03-31 | 239.59 | 3.19 | 246.69 |
| 2018-12-31 | 90.09 | 0.00 | 101.32 |
| 2018-09-30 | 103.58 | 0.00 | 109.48 |
| 2018-06-30 | 113.55 | 0.00 | 119.11 |
| 2018-03-31 | 123.87 | 0.00 | 127.46 |
| 2017-12-31 | 68.52 | 0.00 | 73.00 |
| 2017-09-30 | 76.26 | 0.00 | 79.17 |
| 2017-06-30 | 74.07 | 0.00 | 77.09 |
| 2017-03-31 | 19.92 | 0.00 | 21.36 |
| 2016-12-31 | 19.92 | 0.00 | 21.36 |
| 2016-09-30 | 5.44 | 0.00 | 8.21 |
| 2016-03-31 | 14.01 | 0.00 | 15.07 |
| 2015-12-31 | 17.15 | 0.00 | 17.98 |
| 2015-09-30 | 1.85 | 0.00 | 1.58 |
| 2014-12-31 | 3.47 | 0.00 | 3.87 |
| 2013-12-31 | 2.74 | 0.00 | 3.04 |
- UroGen Pharma's level of debt (1.3%) compared to net worth is satisfactory (less than 40%).
- The level of debt compared to net worth has increased over the past 5 years (0% vs 1.3% today).
CASH RUNWAY ANALYSIS
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
- UroGen Pharma has sufficient cash runway for more than 3 years based on current free cash flow.
- UroGen Pharma has sufficient cash runway for 2.8 years if free cash flow continues to grow at historical rates of 85% each year.
Financial health checks
We assess UroGen Pharma's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) UroGen Pharma has a total score of 5/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
Dividends
What is UroGen Pharma's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
$2,000 of
UroGen Pharma
shares you are expected to receive
$0
in your first year as a dividend.
Dividend Amount
- Unable to evaluate UroGen Pharma's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate UroGen Pharma's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 7 Analyst Estimates (S&P Global) | See Below |
| Global Biotechs Industry Average Dividend Yield | Market Cap Weighted Average of 19 Stocks | 2.4% |
| United States of America Market Average Dividend Yield | Market Cap Weighted Average of 2000 Stocks | 2.5% |
| United States of America Minimum Threshold Dividend Yield | 10th Percentile | 0.8% |
| United States of America Bottom 25% Dividend Yield | 25th Percentile | 1.4% |
| United States of America Top 25% Dividend Yield | 75th Percentile | 3.7% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
| Date (Data in $) | Dividend per Share (annual) | Avg. No. Analysts |
|---|---|---|
| 2023-12-31 | ||
| 2022-12-31 | ||
| 2021-12-31 | ||
| 2020-12-31 | ||
| 2019-12-31 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to perform a dividend volatility check as UroGen Pharma has not reported any payouts.
- Unable to verify if UroGen Pharma's dividend has been increasing as the company has not reported any payouts.
Income/ dividend checks
We assess UroGen Pharma's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can UroGen Pharma afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) UroGen Pharma has a total score of 0/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
Management
CEO
| AGE | 56 |
| TENURE AS CEO | 0.3 years |
CEO Bio
Ms. Elizabeth A. Barrett, also known as Liz, has been President, Chief Executive Officer and Director of UroGen Pharma Ltd. since January 3, 2019. She served as Chief Executive Officer of Novartis Oncology at Novartis AG since February 1, 2018 until December 31, 2018. Ms. Barrett served as the Regional President of US Oncology Business Unit at Pfizer Inc. since March 23, 2009. Ms. Barrett has over 30 years of management expertise and a proven track record in building profitable organizations, working in multi-national companies with international experience and launching and expanding new businesses. She served as Vice President & General Manager for Oncology Business Unit at Cephalon Inc., where she successfully launched it into oncology in an integrated business unit. Ms. Barrett oversaw the marketing, sales and medical affairs organizations and was responsible for developing the short and long term plans to build an oncology business. Her previous oncology experience also includes managing Johnson & Johnson's cancer therapeutics business and overseeing its new business development and licensing and acquisitions. At Johnson & Johnson she also served as Worldwide Vice President of Sales and Marketing for Veridex, LLC and Vice President of the Critical Care and Surgery Franchise for Ortho Biotech, Inc. She is Director of Sage Therapeutics, Inc. since January 22, 2019. Ms. Barrett has received numerous awards from industry organizations including TWIN (Tribute to Women in the Industry), DTC Marketer of the Year, VP Sales/Marketing Award, HBA Rising Star, Women's Leadership Initiative Ambassador and Outstanding Marketer of the Year. She started her career at Kraft Foods Group Inc. She holds a Bachelor of Science in Business Administration from the University of Louisiana in Lafayette, Louisiana and a Masters in Business Administration-Marketing from St. Joseph's University in Philadelphia, Pennsylvania.
CEO Compensation
- Insufficient data for Liz to compare compensation growth.
- Insufficient data for Liz to establish whether their remuneration is reasonable compared to companies of similar size in United States of America.
Management Team Tenure
Average tenure and age of the UroGen Pharma management team in years:
- The average tenure for the UroGen Pharma management team is less than 2 years, this suggests a new team.
Management Team
Liz Barrett
President
56
0.3 yrs
Peter Pfreundschuh
CFO & Secretary
49
0.8 yrs
Stephen Mullennix
Chief Operating Officer
1.3 yrs
Kate Bechtold
Director of Corporate Communications & Investor Relations
1.3 yrs
Sari Prutchi-Sagiv
Marketing Director
Mark Schoenberg
Chief Medical Officer
60
1.4 yrs
Elyse Seltzer
Senior Vice President of Clinical Development
53
1.4 yrs
Woody Bryan
Senior Vice President of Business Development
54
0.7 yrs
Marina Konorty
Chief Chemist
Gil Hakim
Consultant
48
0.8 yrs
Board of Directors Tenure
Average tenure and age of the UroGen Pharma board of directors in years:
- The average tenure for the UroGen Pharma board of directors is less than 3 years, this suggests a new board.
Board of Directors
Liz Barrett
President
56
0.3 yrs
Herbert Lepor
Chairman of Scientific Advisory Board
Kate Falberg
Director
57
2.1 yrs
Cindy Butitta
Director
64
1.6 yrs
Fred Witjes
Member of Scientific Advisory Board
Jack Baniel
Member of Scientific Advisory Board
Ran Nussbaum
Director
45
6 yrs
Stuart Holden
Director
75
3.4 yrs
Fred Cohen
Director
62
2 yrs
Shawn Tomasello
Director
59
0.8 yrs
Who owns this company?
Recent Insider Trading
- UroGen Pharma insiders have sold more shares than they have bought in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price ($) | Value ($) | |
|---|---|---|---|---|---|---|---|---|---|---|
| 22. Mar 19 | Buy | Mark Schoenberg | Individual | 21. Mar 19 | 21. Mar 19 | 272 | $37.01 | $10,066 | ||
| 08. Mar 19 | Sell | Mark Schoenberg | Individual | 06. Mar 19 | 06. Mar 19 | -949 | $37.30 | $-35,398 | ||
| 24. May 18 | Sell | Moshe Arkin | Individual | 09. May 18 | 23. May 18 | -194,179 | $62.56 | $-12,005,844 | ||
Management checks
We assess UroGen Pharma's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) UroGen Pharma has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
News
Simply Wall St News
Does The UroGen Pharma Ltd. (NASDAQ:URGN) Share Price Fall With The Market?
Some stocks mimic the volatility of the market quite closely, while others demonstrate muted, exagerrated or uncorrelated price movements. … Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). … A stock with a beta greater than one is more sensitive to broader market movements than a stock with a beta of less than one.
Simply Wall St - – Full articleHow Much Are UroGen Pharma Ltd. (NASDAQ:URGN) Insiders Taking Off The Table?
So we'll take a look at whether insiders have been buying or selling shares in UroGen Pharma Ltd. … UroGen Pharma Insider Transactions Over The Last Year. … In the last twelve months, the biggest single sale by an insider was when the , Moshe Arkin, sold US$12m worth of shares at a price of US$62.56 per share.
Simply Wall St - – Full articleImagine Owning UroGen Pharma (NASDAQ:URGN) And Wondering If The 37% Share Price Slide Is Justified
Because UroGen Pharma hasn't been listed for many years, the market is still learning about how the business performs. … It seems likely some shareholders believe that UroGen Pharma has the funding to invent a new product before too long. … When it last reported its balance sheet in December 2018, UroGen Pharma had net cash of US$88m.
Simply Wall St - – Full articleUroGen Pharma Ltd. (NASDAQ:URGN) Is Trading At A 31.84% Discount
Help shape the future of investing tools and you could win a $250 gift card! … by taking the expected future cash flows and discounting them to today's value. … Discounted Cash Flows (DCF)
Simply Wall St - – Full articleHow Much Are UroGen Pharma Ltd. (NASDAQ:URGN) Insiders Taking Off The Table?
The Last 12 Months Of Insider Transactions At UroGen Pharma. … In the last twelve months, the biggest single sale by an insider was when Moshe Arkin sold US$12m worth of shares at a price of US$62.56 per share. … Moshe Arkin was the only individual insider to sell shares in the last twelve months
Simply Wall St - – Full articleCan We See Significant Insider Ownership On The UroGen Pharma Ltd. (NASDAQ:URGN) Share Register?
The big shareholder groups in UroGen Pharma Ltd. … With a market capitalization of US$727m, UroGen Pharma is a small cap stock, so it might not be well known by many institutional investors. … View our latest analysis for UroGen Pharma
Simply Wall St - – Full articleHow Financially Strong Is UroGen Pharma Ltd (NASDAQ:URGN)?
UroGen Pharma Ltd (NASDAQ:URGN), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. … Does URGN's growth rate justify its decision for financial flexibility over lower cost of capital. … There are well-known benefits of including debt in capital structure, primarily a lower cost of capital
Simply Wall St - – Full articleIs UroGen Pharma Ltd's (NASDAQ:URGN) Balance Sheet A Threat To Its Future?
UroGen Pharma Ltd (NASDAQ:URGN), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. … However, the trade-off is URGN will have to follow strict debt obligations which will reduce its financial flexibility. … Is URGN growing fast enough to value financial flexibility over lower cost of capital
Simply Wall St - – Full articleCompany Info
Description
UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. The company’s lead product candidates, UGN-101 and UGN-102 are proprietary formulations of the chemotherapy drug mitomycin, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy. It is developing its product candidates as chemoablation agents, which are designed to remove tumors by non-surgical means, to treat various forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma, and low-grade bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins. The company was incorporated in 2004 and is based in New York, New York.
Details
| Name: | UroGen Pharma Ltd. |
| URGN | |
| Exchange: | NasdaqGM |
| Founded: | 2004 |
| $795,896,514 | |
| 20,791,445 | |
| Website: | http://www.urogen.com |
| Address: |
UroGen Pharma Ltd. 499 Park Avenue, New York, New York, 10014, United States |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| NasdaqGM | URGN | Ordinary Shares | Nasdaq Global Market | US | USD | 04. May 2017 | |
| DB | UR8 | Ordinary Shares | Deutsche Boerse AG | DE | EUR | 04. May 2017 | |
| LSE | 0XOD | Ordinary Shares | London Stock Exchange | GB | USD | 04. May 2017 |
Number of employees
Current staff
Industry
| Biotechnology | |
| Pharmaceuticals & Biotech |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/05/20 03:21 |
| End of day share price update: | 2019/05/17 00:00 |
| Last estimates confirmation: | 2019/05/15 |
| Last earnings filing: | 2019/05/09 |
| Last earnings reported: | 2019/03/31 |
| Last annual earnings reported: | 2018/12/31 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
